FDA Guidance on Manufacturing During COVID-19 and High Absenteeism

CDER discusses updates regarding policy and approaches toward manufacturing and high absenteeism during the COVID-19 Public Health Emergency (PHE).

Presenters:
CDR Tara Gooen Bizjak
Director
Manufacturing Quality Guidance and Policy Staff| CDER

CDR Emily Thakur, RPh
Team Leader
Drug Shortage Staff | CDER
Learn more at: https://www.fda.gov/drugs/news-events-human-drugs/manufacturing-supply-chain-and-inspections-during-covid19-public-health-emergency-08252021-08252021
-------------------- 
FDA CDER’s Small Business and Industry Assistance (SBIA) educates and provides assistance in understanding the regulatory aspects of human drug products & clinical research.  
 
Upcoming Training - https://www.fda.gov/cdersbia
SBIA Listserv - https://public.govdelivery.com/accounts/USFDA/subscriber/new?topic_id=USFDA_352
SBIA 2021 Playlist - https://youtube.com/playlist?list=PLey4Qe-UxcxYS1MaTusSgyifQDqdeepyD
SBIA LinkedIn - https://www.linkedin.com/showcase/cder-small-business-and-industry-assistance
SBIA Training Resources - https://www.fda.gov/cdersbialearn
Twitter - https://twitter.com/FDA_Drug_Info
Email - CDERSBIA@fda.hhs.gov  
Phone - (301) 796-6707 I (866) 405-5367

Видео FDA Guidance on Manufacturing During COVID-19 and High Absenteeism канала U.S. Food and Drug Administration